FDA approves alectinib as adjuvant treatment for ALK-positive non-small cell lung cancer
FDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today the Phase III STARGLO study met its primary endpoint of overall survival. The study demonstrated that people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have received at least one prior line of therapy and are not candidates for autologous stem cell transplant, lived longer when treated with Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) versus Rituxan® (rituximab) in combination with GemOx. Safety of the combination appeared consistent with the known safety profiles of the individual medicines. The data will be submitted to health authorities and shared at an upcoming medical meeting.
Genentech’s Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
Roche’s Genentech unit will cut 3% of workers, a spokesperson told Endpoints News Wednesday, making it the latest drugmaker to announce staffing reductions in recent weeks.
Longtime oncology commercial leader Chip Romp is making a creative leap and joining the board of directors at design-focused healthcare agency minds + assembly.
Genentech`s Biologic Xolair (omalizumab) Receives Approval in the U.S.
Genentech`s Biologic Lucentis (ranibizumab) Receives Approval in the U.S.
Genentech`s Biologic Pulmozyme (dornase alfa) Receives Approval in the U.S.
Genentech is taking its spinal muscular atrophy awareness efforts to New York with an original musical comedy. The show, called “Most Likely Not To…” will be performed on Feb. 29, also known as Rare Disease Day, with a cast that includes actors, writers and performers with SMA.